l -γ-羧基谷氨酸 (Gla) 是一种罕见的氨基酸,可与矿物表面和金属离子紧密结合。在此,我们报告了N -α- Fmoc- l -γ-羧基谷氨酸 γ,γ'-叔丁酯(Fmoc-Gla(O t Bu) 2 -OH)的合成,这是一种基于 Fmoc 的适当保护的类似物。固相肽合成。该残留物是使用一种新型手性 Cu(II) 络合物合成的,其基于结构的设计灵感来自蓝铜蛋白 rusticyanin。在铜存在下,甘氨酸和新型配体 ( S )-2-( N- (2-甲硫基)苄基脯基)氨基二苯甲酮之间通过Shiff碱形成形成五配位络合物。迈克尔加法亚甲基丙二酸叔丁酯与复合物甘氨酸部分的 α-碳以非对映选择性方式发生。所得的 ( S , S )-复合非对映体可以很容易地通过色谱法纯化。金属配合物分解,然后 Fmoc 保护提供对映异构纯氨基酸。使用这种新型手性络合物,Fmoc-Gla(O t Bu) 2 -OH的
l -γ-羧基谷氨酸 (Gla) 是一种罕见的氨基酸,可与矿物表面和金属离子紧密结合。在此,我们报告了N -α- Fmoc- l -γ-羧基谷氨酸 γ,γ'-叔丁酯(Fmoc-Gla(O t Bu) 2 -OH)的合成,这是一种基于 Fmoc 的适当保护的类似物。固相肽合成。该残留物是使用一种新型手性 Cu(II) 络合物合成的,其基于结构的设计灵感来自蓝铜蛋白 rusticyanin。在铜存在下,甘氨酸和新型配体 ( S )-2-( N- (2-甲硫基)苄基脯基)氨基二苯甲酮之间通过Shiff碱形成形成五配位络合物。迈克尔加法亚甲基丙二酸叔丁酯与复合物甘氨酸部分的 α-碳以非对映选择性方式发生。所得的 ( S , S )-复合非对映体可以很容易地通过色谱法纯化。金属配合物分解,然后 Fmoc 保护提供对映异构纯氨基酸。使用这种新型手性络合物,Fmoc-Gla(O t Bu) 2 -OH的
[EN] FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO<br/>[FR] AGENTS THÉRAPEUTIQUES ACTIVÉS PAR FAP, ET UTILISATIONS ASSOCIÉES
申请人:TUFTS COLLEGE
公开号:WO2015192123A1
公开(公告)日:2015-12-17
Disclosed are prodrugs of cytotoxic anthracyclines (such as doxorubicin) and other therapeutic agents that are selectively cleaved and activated by fibroblast activating protein (FAP). The prodrugs are useful for targeted delivery of cytotoxic and other agents to FAP- expressing tissues, including cancer (e.g., solid tumors). Also provided are pharmaceutical compounds comprising the prodrugs, as well as methods of using the prodrugs to treat a disorder characterized by FAP upregulation, e.g., cancer, fibrosis, and inflammation.
[EN] COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE<br/>[FR] COMPOSITIONS ET PROCÉDÉS D'INHIBITION D'UNE POLYMÉRASE VIRALE
申请人:BIOCRYST PHARM INC
公开号:WO2013158746A1
公开(公告)日:2013-10-24
Provided are compounds of Formula (I) as described herein. Compounds of Formula (I) are useful in methods of inhibiting viral RNA polymerase activity and viral replication. Also provided are pharmaceutical compositions comprising compounds of Formula (I), as well as methods of treating viral infections using compounds of Formula (I).
An in-tether sulfilimine chiral center induces helicity in short peptides
作者:Huacan Lin、Yixiang Jiang、Qingzhou Zhang、Kuan Hu、Zigang Li
DOI:10.1039/c6cc04508a
日期:——
A precisely positioned sulfilimine chiralcenter in the tether of a stabilized peptide would determine the peptides' secondary structure. The peptide sulfilimines could be prepared by a facile chloramine T...
稳定肽链中精确定位的硫亚胺手性中心将决定肽的二级结构。可以通过简便的氯胺T ...
Novel modified chiral NiII complexes with the Schiff bases of (E)-and (Z)-2-aminobut-2-enoic acids: Synthesis and study
作者:A. S. Saghiyan、L. L. Manasyan、S. A. Dadayan、S. G. Petrosyan、A. A. Petrosyan、V. I. Maleev、V. N. Khrustalev
DOI:10.1007/s11172-006-0276-1
日期:2006.3
NiII complexes with the Schiff bases of (E)-and (Z)-2-aminobut-2-enoic acids were obtained with (S)-N-(2-benzoylphenyl)-1-(2-chlorobenzyl)pyrrolidine-2-carboxamide and (S)-N-(2-benzoylphenyl)-1-(3,4-dimethylbenzyl)pyrrolidine-2-carboxamide as new chiral auxiliaries. Asymmetric addition of nucleophiles to the C=C bond of these complexes was studied.
COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE
申请人:Kotian Pravin L.
公开号:US20150191472A1
公开(公告)日:2015-07-09
Provided are compounds of Formula I:
as described herein. Compounds of Formula I are useful in methods of inhibiting viral RNA polymerase activity and viral replication. Also provided are pharmaceutical compositions comprising compounds of Formula I, as well as methods of treating viral infections using compounds of Formula I.